
Wynclark Pharmaceuticals Private Limited
Sells medicines and general items, incorporated in 2007, based in Hyderabad.
Sells medicines and general items, incorporated in 2007, based in Hyderabad.
Wynclark Pharmaceuticals Private Limited (WPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 February 2007 and has a history of 18 years and three months. Its registered office is in Rangareddy, Telangana, India.
The Corporate was formerly known as Medplus Pathlabs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 14.08 Cr and a paid-up capital of Rs 14.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Wynclark Pharmaceuticals Private Limited India are Sujit Mahato as CFO and Riti Gupta as Company Secretary. Satya Kammila, Bhaskar Cherukupalli, and Paidiwar Srinivas serve as directors at the Company.
Rangareddy, Telangana, India
+91-XXXXXXXXXX
U24239TG2007PTC052676
052676
Private Limited Indian Non-Government Company
08 Feb 2007
10 Jul 2024
31 Mar 2024
Unlisted
Roc Hyderabad
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sujit Mahato ![]() | CFO | 16-Nov-2022 | Current |
Riti Gupta | Company Secretary | 10-Jan-2023 | Current |
Name | Designation | Appointment Date | Status |
---|---|---|---|
Satya Kammila ![]() | Whole-Time Director | 29-Sep-2021 | Current |
Bhaskar Cherukupalli ![]() | Director | 29-Sep-2021 | Current |
Paidiwar Srinivas ![]() | Director | 03-Aug-2013 | Current |
Wynclark Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.13% increase. The company also saw a substantial improvement in profitability, with a 24.69% increase in profit. The company's net worth Soared by an impressive increase of 61.48%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Wynclark Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Sujit Mahato and Bhaskar Cherukupalli are mutual person
Bhaskar Cherukupalli and Paidiwar Srinivas are mutual person
Bhaskar Cherukupalli is a mutual person
Bhaskar Cherukupalli is a mutual person
Satya Kammila, Bhaskar Cherukupalli and 1 more are mutual person
Satya Kammila and Paidiwar Srinivas are mutual person
There are no open charges registered against the company as per our records.
Wynclark Pharmaceuticals has a workforce of 7 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Wynclark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wynclark Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Wynclark Pharmaceuticals Private Limited last Annual general meeting of members was held on 10 Jul 2024 as per latest MCA records.
Wynclark Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Riti Gupta was appointed as a Company Secretary was appointed as a Company Secretary on 10 Jan 2023 & has been associated with this company since 2 years 4 months .
Sujit Kumar Mahato was appointed as a Cfo was appointed as a Cfo on 16 Nov 2022 & has been associated with this company since 2 years 5 months .
Satya Murali Krishna Kammila was appointed as a Whole-Time Director was appointed as a Whole-Time Director on 29 Sep 2021 & has been associated with this company since 3 years 7 months .
Bhaskar Reddy Cherukupalli was appointed as a Director was appointed as a Director on 29 Sep 2021 & has been associated with this company since 3 years 7 months .
Wynclark Pharmaceuticals Private Limited was incorporated on 08 Feb 2007.
The authorized share capital of Wynclark Pharmaceuticals Private Limited is ₹ 14.08 Cr and paid-up capital is ₹ 14.08 Cr.
Currently 5 directors are associated with Wynclark Pharmaceuticals Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Wynclark Pharmaceuticals Private Limited is Ground Floor 12-7-20/64/2 Survey No. 793 Goods Shed Road Moosapet Kukatpally, India, Hyderabad, Telangana, 500018.
The corporate identification number (CIN) of Wynclark Pharmaceuticals Private Limited is U24239TG2007PTC052676 and the company number is 052676 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Wynclark Pharmaceuticals Private Limited has risen by 40.13%.
As Per 2023 financial reports, 7 employees are currently employed by Wynclark Pharmaceuticals Private Limited.
The financial reports for the fiscal year 2023 indicates that The net worth of Wynclark Pharmaceuticals Private Limited has experienced an upsurge of 61.48%.
The most recent Balance Sheet for Wynclark Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2024.
Search company & director profiles for free and gain access to critical business data.
MG
AG
SM